A few days ago, Transparent Market Research (TMR) released the latest market analysis report on the nasal polyp treatment market during the forecast period from 2019 to 2027.
According to the report, the global nasal polyp treatment market was valued at approximately US$3.
9 billion in 2018, and the compound annual growth rate (CAGR) is expected to reach 5% from 2019 to 2027.
Due to the increasing number of elderly people suffering from chronic rhinosinusitis (CRSwNP) of nasal polyps, otolaryngologists and surgeons in developed areas are using more frequent minimally invasive surgery, and the treatment channels for nasal polyps are becoming more abundant.
TMR expects The global nasal polyp treatment market share will be promoted.
North America accounted for a major share in the global nasal polyp treatment market in 2018.
For example, there is strong demand for sinus implants in the United States.
From 2019 to 2027, the nasal polyp treatment market in the Asia-Pacific region is expected to grow at a high compound annual growth rate of 6% due to the surge in the number of target patients suffering from inflammatory respiratory diseases, which is likely to promote the inclusion of India and The number of nasal polyps treatment operations in emerging markets including China has increased.
Global CRSwNP prevalence drives market growthGlobal CRSwNP prevalence drives market growth
TMR predicts that from 2019 to 2027, the prevalence of inflammatory and respiratory diseases such as CRSwNP, asthma, nasal polyps and allergic rhinitis will increase the global nasal polyp treatment market.
Chronic rhinosinusitis (CRS) is a rhinitis disease that affects the tissues inside the nasal cavity and paranasal sinuses, causing symptoms to last from 8 weeks to 12 weeks or longer.
The disease can occur with or without nasal polyps.
CRS is considered to be a serious nasal disease, with a prevalence of 4.
7% in elderly people 60 years and older.
In addition, the disease is also the sixth most common chronic disease affecting the elderly population.
Therefore, the increasing prevalence and treatment burden of chronic respiratory diseases such as CRSwNP will drive the market demand for treatments and therapies by patients.
This may lead to an increase in the number of sinus surgery, which may accelerate the growth of the global nasal polyp treatment market in the next few years.
Existing treatment methodsExisting treatment methods
In terms of treatment, the global nasal polyp treatment market can be divided into drug therapy and surgery.
Drug therapy can be divided into antibiotics, corticosteroids, leukotriene inhibitors and so on.
The surgical part can be divided into polypectomy and functional endoscopic sinus surgery (FESS).
The field of drug therapy dominated the global nasal polyp treatment market in 2018, and this trend is expected to continue during the forecast period.
Intranasal steroid sprays, systemic and oral corticosteroids, nasal irrigation saline, and antibiotics are widely used to treat CRSwNP patients with nasal polyps.
In addition, the increasing demand for topical and systemic corticosteroids is expected to minimize the size of nasal polyps and prevent nasal polyps from growing again, which is expected to promote the growth of the nasal polyp treatment market.
Hospitals are expected to become the growth point of surgical treatmentHospitals are expected to become the growth point of surgical treatment
Surgical treatments for nasal polyps include: polypectomy and functional endoscopic sinus surgery (FESS), which are mainly performed in ambulatory surgery centers, hospitals and specialist clinics.
As the number of patients diagnosed with nasal polyps worldwide is increasing, resulting in a rapid increase in sinus surgery performed in operating rooms, the market segment of hospitals is expected to grow at a high CAGR during the forecast period.
TMR believes that the growth of this sector is attributable to the increased availability of professional nursing services in hospitals and the emergence of qualified healthcare professionals in hospitals.
It is expected that in the next few years, the market for outpatient surgery centers will grow rapidly.
Due to higher efficiency, higher patient satisfaction, shortest hospital stay, and lower infection rate, the number of patients transferred from the sinus surgery operating room to the outpatient surgery center increases, which may promote the growth of the nasal polyp treatment market.
North America has outstanding performance and the Asia-Pacific region is an incremental opportunity for the futureNorth America has outstanding performance and the Asia-Pacific region is an incremental opportunity for the future
In terms of regions, the global nasal polyp treatment market has been subdivided into North America, Europe, Latin America, Asia Pacific, and the Middle East and Africa.
It is expected that during the forecast period, due to the increase in the number of patients with nasal polyps, North America will continue to occupy a leading share in the global nasal polyp treatment market.
For example, the United States reports nearly 200,000 new cases of nasal polyps every year, which is expected to increase the treatment rate of nasal polyps.
In turn, this is expected to drive patient demand for medical treatments and increase the number of sinus surgeries performed in the United States.
In addition, the payment and reimbursement program for nasal polyp treatment in the United States may further promote the North American nasal polyp treatment market.
It is expected that the nasal polyp treatment market in the Asia-Pacific region will grow rapidly in the next few years.
It is expected that China, India, and South Korea will usher in a lucrative nasal polyps market at the time of forecast, because the number of patients affected by nasal polyps CRSwNP is increasing in this region.
According to the National Center for Biotechnology Information (NCBI), approximately 8% of the Chinese population and 6.
9% of the Korean population are affected by chronic rhinosinusitis.
The disease may occur together with nasal polyps and may cause nasal obstruction, facial pain, and sinus inflammation.
These unbearable symptoms may also drive the demand for treatment and drugs for patients in emerging markets.
Market growth strategies of major pharmaceutical manufacturers of nasal polypsMarket growth strategies of major pharmaceutical manufacturers of nasal polyps
The major players operating in the global nasal polyp treatment market are Merck, Sanofi, Pfizer, GlaxoSmithKline, Novartis, as well as Intersect ENT and OptiNose US, Inc.
, as well as Roche and Regeneron.
The main market activities of these companies include strategic cooperation and partnerships engaged in R&D activities and new product launches to expand the product range and customer base.
In April 2018, Intersect ENT announced the launch of SINUVA sinus implants in the United States.
Sinova sinus implant is a mometasone furoate steroid-eluting sinus implant used to treat recurrent nasal polyps that have undergone sinus surgery.
Four months after obtaining US FDA approval, Sanofi and its partner Regeneron announced in October 2019 that the European Commission (EC) had approved Dupixent (dupilumab) as an add-on therapy for intranasal corticosteroids.
Treatment of adult patients with chronic rhinosinusitis (CRSwNP) with nasal polyps who cannot provide adequate disease control with systemic corticosteroids and/or surgery.
In April 2020, GlaxoSmithKline announced that its anti-IL-5 monoclonal antibody Nucala (mepolizumab) has reached the test in the key phase 3 clinical trial SYNAPSE for the treatment of patients with chronic rhinosinusitis (CRSwNP) with nasal polyps The primary endpoint and critical secondary endpoint.
In December 2020, the Xolair (omalizumab) pre-filled syringe jointly developed by Roche and Novartis was approved for the treatment of nasal polyps, as an add-on therapy to intranasal corticosteroids (INC), for the treatment of inadequate control with INC.
Adult patients (≥18 years of age) with severe chronic rhinosinusitis with nasal polyps (CRSwNP).
In May 2021, OptiNose announced the financial report for the first quarter of fiscal year 2021.
The net profit attributable to common shareholders of the parent company was US$26,053, a year-on-year increase of 9.
71%; operating income was US$11.
96 million, a year-on-year increase of 69.
The main product of OptiNose is XHANCE nasal spray, which uses a unique breathing exhalation system and is an effective anti-inflammatory corticosteroid hormone for the treatment of chronic sinusitis and nasal polyps.
Reference source: Nasal Polyps Treatment Market: Pharmacological therapies segment dominated the global market